Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection?

JACC Heart Fail. 2022 Aug;10(8):568-570. doi: 10.1016/j.jchf.2022.04.014. Epub 2022 Jul 6.

Authors

Michel G Khouri¹, Stephen J Greene²

Affiliations

¹ Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: michel.khouri@duke.edu.
² Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA.

PMID: 35902160
DOI: 10.1016/j.jchf.2022.04.014

No abstract available

Keywords: SGLT2 inhibitors; anthracyclines; cardiotoxicity; chemotherapy; heart failure.

Publication types

Editorial
Comment

MeSH terms

Anthracyclines / adverse effects
Glucose
Heart Failure* / drug therapy
Humans
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Symporters*

Substances

Anthracyclines
Sodium-Glucose Transporter 2 Inhibitors
Symporters
Sodium
Glucose